Ryan Elliott

🫁 Just passing on what I thought was a very nice diagram from Med G for respiratory physical examination. Always nice to have some materials on-hand for learners. #medsky #IMsky

Jorge Castillo, MD, shares data on an all-oral, non-chemo, fixed-duration regimen for Waldenström macroglobulinemia using pirtobrutinib and venetoclax. The combination delivered rapid, profound and 100% overall responses with manageable side effects and high rate of deep responses. #ASH25

Wow!! 🔥🔥 CDK4/6 inhibition prevents selection of #ClonalHematopoiesis with DNA-damage repair mutations after chemotherapy! Awesome presentation from Irenaeus Chan from @kellybolton.bsky.social lab! #ASH25

#ASH25 let’s goooooo

📚 This T-cell NHL diagnostic slide has been circulating and provides a nice framework
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL | OncLive Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL
#CLL #Hematology
www.onclive.com/view/final-c...

All signed up for the 2025 ASH Annual Meeting. Looking forward to it! #hemesky #ASH25

🩸 ISTH DIC score (overt ≥ 5)
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme

Join us on October 25 for a packed day of thrombosis education for healthcare professionals. Register today at thrombosiscanada.ca/2025Conference

Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...

🩺 Differentiation Syndrome
- complication that can occur during treatment of APL w/ ATRA+ATO

Clinical:
⬆️ WBCs
⬆️ Fever
⬆️ edema/body weight/pulmonary infiltrates

Mgmt:
- high-dose steroids
- cytoreduction
- antipyretics / cxs / abx for FN
- diuresis

#hemesky #hemeonc #medsky #APL #APML #leukemia

Not hard to tell that I’m currently on thrombosis! Having a good experience with the team here at McMaster. #thrombosis #hemesky #hematology

Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation Compelling evidence supports the need to update the 2001 definition and diagnosis of disseminated intravascular coagulation (DIC) to reflect our curre…

"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation."
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...

🩸📖 NEJM 2003: CLOT trial - 676 patients w/ cancer-associated thrombosis (CAT) - Dalteparin vs warfarin.

Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).

Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.

#hemesky #thrombosis #medsky

🩸Cancer-associated Thrombosis Trials: LMWH more effective than VKAs

CANTHANOX 2002:
Enoxaparin vs VKA

CLOT 2003:
Dalteparin vs VKA

ONCENOX 2006:
Enoxaparin vs VKA

LITE 2006:
Tinzaparin vs VKA

CATCH 2015:
Tinzaparin vs VKA

#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc

CARAVAGGIO 2020 (1,170 pts):

Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis

Lesson from this past week:

Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis

Ven is effective (91% ORR) and well tolerated in octogenarians, but 43% hd treatment holds and 32% prolonged ramp-up. buff.ly/lNgBN1r #hemesky

Monoclonal Gammopathy: Paraneoplastic Neuropathy 🧠🩸

AL Amyloidosis: painful + length-dependent + sensory > motor
POEMS: symmetric disabling demyelinating polyneuropathy
DADS-M: distal loss of proprioception + demyelinating + coarse tremor + mild motor weakness

#hemesky #myeloma #medsky #neurosky

Figure 1. Pathogenesis of CML and Mechanism of Action of Available BCR::ABL1 TKIs

Chronic myeloid leukemia is a myeloproliferative neoplasm.

This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.

https://ja.ma/4mlR6ez

Thanks for the added detail! 🔬

Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia

🔬🩸Hemoglobin development (some fundamentals!)

Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2

Fetus
HbF = α2γ2

Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...

Blood film picture of a patient with CML showing a variety of immature and mature white blood cells

Workin. CML in a 27 Year old. #haematology #hematology

💊 Abatacept

Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.

Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.

#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...

This recently published study highlights the prognostic significance of high-risk cytogenetic abnormalities in multiple myeloma. Genetic alterations like t(4;14), del(17p), and +1q are linked to poorer prognosis and shorter survival  #MM #hematology 👉https://bit.ly/3PzY1BT

This looks awesome! 🔬🤩

Congratulations to you! Wishing you good health going forward ♥️